Question 1

What are the key details for the project “Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)”?

Accepted Answer

The project “Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in United States of America. Taiyo aggregates data on it from Grants.gov.

Question 2

What is the latest status of the project “Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)”?

Accepted Answer

The status recorded for “Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)” is archived.

Question 3

Who are the main government, EPC, and private stakeholders for “Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)”?

Accepted Answer

Taiyo maps the stakeholders of “Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)”: government bodies (National Institutes of Health (NIH), US Department of Health and Human Services (HHS), US Government).

Question 4

What is the budget and commercial profile for the project “Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)”?

Accepted Answer

Taiyo normalizes the budget of “Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)” to USD 3860000.

Question 5

Where can I verify the source and access all details for “Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)”?

Accepted Answer

This Taiyo project page references Grants.gov along with the original URL (https://www.grants.gov/web/grants/view-opportunity.html?oppId=310507). Taiyo standardizes official data into a consistent, searchable project profile.

Sponsoring Agency	Obfuscated Data
Company	Obfuscated Data

Original status	archived
Taiyo status	Obfuscated Data
Taiyo last update	00-00-0000
Available timestamps	00-00-0000
Available timestamp type	Obfuscated Data

Contact name	Obfuscated Data
Phone	0000000000
Email	ObfuscatedData@email.com
Address	Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description	The purpose of this Funding Opportunity Announcement (FOA) is to accelerate development of safe and effective long-acting drug delivery systems (LA-DDS) for improved, simplified treatment of HIV-1 in children. This FOA invites applicants engaged in the development of existing LA-DDS platforms at early product development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-1 infected children. Collaborative research partnerships with industry are required.
Original sub-sector	Obfuscated
Original Currency	USD
Original budget	000000000000000
Procurement method	Obfuscated Data
Budget	000000000000000

Region	Obfuscated
Country	Obfuscated
State	Obfuscated Data
County	Obfuscated
Location	Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source reliability	High
Data quality score	100%
Source	Obfuscated Data
URL	obfuscated_data,obfuscateddata.com

Project Type	Obfuscated Data
Article Published Date	Obfuscated Data

Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)

Project Information FAQ

Project Information